AEVs derived from ischemic astrocytes treated with P2Y1R-ANT and MCM containing miR-146a exerted anti-inflammatory effects, reversed the expression of C3d/S100A10 in reactive astrocytes in the post-stroke glial scars, and thereby improved motor function, whereas P2Y1R-ANT solely suppressed C3d expression but did not increase S100A10 levels, which did not facilitate stroke recovery. The gene discussed is S100A10; the disease is stroke disorder.